NCT00744354 - Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

April 30, 2015

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

bortezomib

Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11

DRUG

pegylated liposomal doxorubicin hydrochloride

Intravenous infusion, 30mg/m2, Day 4, each cycle

DRUG

vorinostat

Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.

Trial Locations (4)

Mount Sinai Medical Center, New York

Duke Comprehensive Cancer Center, Durham

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Wake Forest University Comprehensive Cancer Center, Winston-Salem